Regulation of the Antigen Presentation Machinery in Cancer and Its Implication for Immune Surveillance

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2022 Mar 28

PMID 35343573

Authors

Adithya Balasubramanian

Thomas John

Marie-Liesse Asselin-Labat

Affiliations

Soon will be listed here.

Abstract

Evading immune destruction is one of the hallmarks of cancer. A key mechanism of immune evasion deployed by tumour cells is to reduce neoantigen presentation through down-regulation of the antigen presentation machinery. MHC-I and MHC-II proteins are key components of the antigen presentation machinery responsible for neoantigen presentation to CD8+ and CD4+ T lymphocytes, respectively. Their expression in tumour cells is modulated by a complex interplay of genomic, transcriptomic and post translational factors involving multiple intracellular antigen processing pathways. Ongoing research investigates mechanisms invoked by cancer cells to abrogate MHC-I expression and attenuate anti-tumour CD8+ cytotoxic T cell response. The discovery of MHC-II on tumour cells has been less characterized. However, this finding has triggered further interest in utilising tumour-specific MHC-II to harness sustained anti-tumour immunity through the activation of CD4+ T helper cells. Tumour-specific expression of MHC-I and MHC-II has been associated with improved patient survival in most clinical studies. Thus, their reactivation represents an attractive way to unleash anti-tumour immunity. This review provides a comprehensive overview of physiologically conserved or novel mechanisms utilised by tumour cells to reduce MHC-I or MHC-II expression. It outlines current approaches employed at the preclinical and clinical trial interface towards reversing these processes in order to improve response to immunotherapy and survival outcomes for patients with cancer.

Citing Articles

Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer.

Chen Q, Deng D, Zhu H, Li S World J Surg Oncol. 2025; 23(1):12.

PMID: 39810181 PMC: 11730844. DOI: 10.1186/s12957-025-03654-z.

Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies.

Looi C, Loo E, Lim H, Chew Y, Chin K, Cheah S Front Immunol. 2024; 15:1484535.

PMID: 39450176 PMC: 11499120. DOI: 10.3389/fimmu.2024.1484535.

Prognostic Protein Biomarker Screening for Thyroid Carcinoma Based on Cancer Proteomics Profiles.

Xie P, Yin Q, Wang S, Song D Biomedicines. 2024; 12(9).

PMID: 39335579 PMC: 11428938. DOI: 10.3390/biomedicines12092066.

Targeted inhibition of glycogen synthase kinase-3 using 9-ING-41 (elraglusib) enhances CD8 T-cell-reactivity against neuroblastoma cells.

Markovska A, Somers K, Guillaume J, Melief J, Mazar A, Schmitt D Sci Rep. 2024; 14(1):21710.

PMID: 39289439 PMC: 11408500. DOI: 10.1038/s41598-024-72492-y.

Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity.

Rana P, Ignatz-Hoover J, Guo C, Mosley A, Malek E, Federov Y Mol Cancer Ther. 2024; 23(12):1743-1760.

PMID: 39210605 PMC: 11612626. DOI: 10.1158/1535-7163.MCT-23-0931.

References

Benitez R, Godelaine D, Lopez-Nevot M, Brasseur F, Jimenez P, Marchand M . Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens. 1999; 52(6):520-9. DOI: 10.1111/j.1399-0039.1998.tb03082.x. View

Brea E, Oh C, Manchado E, Budhu S, Gejman R, Mo G . Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunol Res. 2016; 4(11):936-947. PMC: 5110210. DOI: 10.1158/2326-6066.CIR-16-0177. View

Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S . Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016; 7:10582. PMC: 4740184. DOI: 10.1038/ncomms10582. View

Hu J, Li L, Chen Y, Liu C, Cui X, Yin L . HLA-DRB1 and HLA-DQB1 methylation changes promote the occurrence and progression of Kazakh ESCC. Epigenetics. 2014; 9(10):1366-73. PMC: 4623353. DOI: 10.4161/15592294.2014.969625. View

Tay R, Richardson E, Toh H . Revisiting the role of CD4 T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2020; 28(1-2):5-17. PMC: 7886651. DOI: 10.1038/s41417-020-0183-x. View

Oh C, Klatt M, Bourne C, Dao T, Dacek M, Brea E . ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome. Cancer Immunol Res. 2019; 7(12):1984-1997. PMC: 6891198. DOI: 10.1158/2326-6066.CIR-19-0056. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Smithy J, Moore L, Pelekanou V, Rehman J, Gaule P, Wong P . Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. J Immunother Cancer. 2017; 5:25. PMC: 5359951. DOI: 10.1186/s40425-017-0229-2. View

Hashwah H, Schmid C, Kasser S, Bertram K, Stelling A, Manz M . Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proc Natl Acad Sci U S A. 2017; 114(36):9701-9706. PMC: 5594639. DOI: 10.1073/pnas.1619555114. View

10.

Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H . Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene. 2004; 23(55):8876-86. DOI: 10.1038/sj.onc.1208144. View

11.

Surmann E, Voigt A, Michel S, Bauer K, Reuschenbach M, Ferrone S . Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunol Immunother. 2014; 64(3):357-66. PMC: 8711774. DOI: 10.1007/s00262-014-1638-4. View

12.

Versteeg R, Noordermeer I, Ruiter D, Schrier P . c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 1988; 7(4):1023-9. PMC: 454430. DOI: 10.1002/j.1460-2075.1988.tb02909.x. View

13.

Muhlethaler-Mottet A, Di Berardino W, Otten L, MACH B . Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity. 1998; 8(2):157-66. DOI: 10.1016/s1074-7613(00)80468-9. View

14.

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

15.

Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

16.

Janitz M, Muhlethaler-Mottet A, Rosowski M, Lauster R . Analysis of the sequence polymorphism within class II transactivator gene promoters. Exp Clin Immunogenet. 2002; 18(4):199-205. DOI: 10.1159/000049198. View

17.

Jongsma M, de Waard A, Raaben M, Zhang T, Cabukusta B, Platzer R . The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity. 2020; 54(1):132-150.e9. PMC: 8722104. DOI: 10.1016/j.immuni.2020.11.003. View

18.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

19.

Cho S, Vijayan S, Yoo J, Watanabe T, Ouda R, An N . MHC class I transactivator NLRC5 in host immunity, cancer and beyond. Immunology. 2020; 162(3):252-261. PMC: 7884647. DOI: 10.1111/imm.13235. View

20.

Kawai T, Akira S . Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007; 13(11):460-9. DOI: 10.1016/j.molmed.2007.09.002. View